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Abstract
Objectives—Our goal was to evaluate the effect of rapamycin, an mTOR inhibitor, in type I and
II human endometrial cancer tumor explants.
Methods—Short-term tissue culture with fresh endometrial cancer tumor explants was
performed. Cell proliferation was assessed by MTS assay after treatment with rapamycin. Akt and
PTEN status were documented by Western blotting. The effect of rapamycin on phosphorylated-
S6 and 4E-BP-1 was also assessed by Western blotting. Real-time RT-PCR was used to quantify
hTERT mRNA expression. Telomere length was determined by terminal restriction fragment
Southern blotting.
Results—Thirteen fresh endometrial cancer tumor explants (nine Type I, four Type II) were
placed in short-term culture and treated with rapamycin. Nine of the endometrial cancer tumors
responded to rapamycin, with a median IC50 of 11.4 nM. Sensitivity to rapamycin was
independent of PTEN and Akt status. Tumors (13/13) had a reduction in phosphorylated-S6 and
10/13 had a reduction in phosphorylated 4E-BP-1. Rapamycin decreased hTERT mRNA
expression in all of the endometrial cancer tumors. Telomere length did not correspond with
responsiveness to this drug.
Conclusions—Rapamycin demonstrated activity in fresh endometrial tumor explants
independent of PTEN and Akt status. Some tumors demonstrated a reduction in phosphorylated-
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S6 and 4E-BP-1 without a significant change in cellular proliferation, suggesting that additional
pathways may modulate cellular proliferation. Thus, mTOR inhibitors may be a useful targeted
therapy for both type I and type II endometrial cancers, but the search remains for a predictive
biomarker of sensitivity to this therapy.
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Background
Endometrial carcinoma is the most common gynecologic malignancy in the United States,
accounting for more than 42,160 cases and 7780 deaths in 2009 [1]. Women with early stage
disease (FIGO stage I and II) and endometrioid histology (type I) have a relatively good
prognosis with surgery alone or surgery plus radiation. However, those patients with
advanced or recurrent disease are unlikely to be cured by surgery, conventional
chemotherapy, radiation or a combination of these modalities. In addition, 20% of women
with be diagnosed with a tumor of either serous or clear cell histology (type II) and even in
the setting of early stage disease (FIGO stage I), these women have a 5-year survival rate of
60% as compared with an 85–90% survival rate in those with stage I endometrioid
adenocarcinoma. Unlike type I endometrial cancers that are associated with obesity and
estrogen excess, there is no clear epidemiologic profile for type II cancers which behave
much more aggressively. As some estimate that the percent of women dying from
endometrial carcinoma has increased by 227% over the past decade, there is a great need to
develop novel targeted agents that can be used alone or in combination with current
treatment strategies.
A dualistic model for the development and progression of endometrial cancer exists that
divides these tumors into type I and type II based on biological, molecular and clinical
parameters [2]. Type I or those tumors of endometrioid histology comprise 80% of cases and
are thought to arise from persistent unopposed estrogen stimulation, which can be either
endogenous or exogenous. Women who develop these tumors are typically perimenopausal
and often have risk factors such as obesity, hyperlipidemia, nulliparity, diabetes mellitus and
insulin resistance, polycystic ovarian syndrome, hypertension and late-onset menopause.
These tumors are preceded by an identifiable premalignant state of hyperplasia and
ultimately, atypical hyperplasia, and are generally estrogen receptor (ER) and progesterone
receptor (PR) positive. Genetic alterations associated with these tumors include PTEN
deletions or mutations (36–83%), microsatellite instability (20–40%), mutations of K-ras
(15–30%) and gain of function mutations in β-catenin (25–40%) [3–5].
In contrast, type II or those tumors of atypical histologies such as serous and clear cell
carcinomas have no association with excess endogenous or exogenous estrogen and have no
recognized risk factors. These tumors generally occur in postmenopausal women in the
setting of an atrophic endometrium. Type II tumors behave much more aggressively and
show a propensity for deep invasion, lymphovascular permeation and distant spread. ER and
PR are generally negative or weakly positive. A precursor lesion is not as well defined but
an in situ form of this type of carcinoma has been described and is referred to as endometrial
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intraepithelial carcinoma (EIC) [6]. The molecular genetic profile for these tumors is
different than type I tumors and is associated with aneuploidy, p53 mutations (80–90%), p16
inactivation (40%), overexpression of HER-2/neu (40–80%) and E-cadherin alterations (80–
90%) [3–5].
As our knowledge has evolved of the underlying molecular mechanisms involved in
endometrial cancer development and progression, many potential targeted therapeutic agents
are being actively investigated [7]. Loss of PTEN expression is one of the most prevalent
molecular abnormalities associated with endometrial cancers and occurs in an estimated 36–
83% of type I endometrial cancers. Unlike most other tumor types, loss of PTEN expression
is observed in premalignant lesions of the endometrium, suggesting that PTEN loss may be a
potential initiator of endometrial cancer development [8]. Wild-type PTEN downregulates
the PI3K/Akt/mTOR signaling pathway, which transduces extracellular growth regulatory
signals to intracellular mediators of growth and cell survival [9]. Loss of PTEN results in
constitutive activation of Akt and subsequently leads to promotion of cellular proliferation
and resistance to apoptosis. Therefore, mTOR is a promising target for endometrial cancer
therapy, and clinical trials of mTOR inhibitors are currently underway for this disease.
mTOR inhibitors such as rapamycin exert their anti-proliferative effects through inhibition
of the serine/threonine kinase, mammalian target of rapamycin (mTOR), by forming a
complex with one of the immunophilin family of FK506 binding proteins, FKBP12 [10,11].
The inhibition of mTOR prevents phosphorylation and activation of S6K1 and 4E-binding
protein 1 (4E-BP-1), which ultimately results in the inhibition of translation of critical
mRNAs involved in cell cycle progression [10,11]. We have previously demonstrated that
rapamycin profoundly inhibits cell proliferation through G1 cell cycle arrest in established
endometrial cancer cell lines [12]. Our goal was to expand on our previous work and assess




Rapamycin was purchased from Sigma (St. Louis, MO) and dissolved in DMSO. The anti-
wild-type PTEN antibody, anti-phosphorylated-ser473-Akt antibody, anti-phosphorylated-
ser235/236-S6 antibody, anti-total-S6 antibody, anti-phosphorylated-ser65-4E-BP-1
antibody and anti-total-4E-BP-1 antibody were purchased from Cell Signaling (Danvers,
MA). The anti-estrogen receptor antibody, the anti-progesterone receptor antibody and the
anti-β-actin antibody were from Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced
Chemiluminescence Western blotting detection reagents (ECL) were from Amersham
(Arlington Heights, IL).
Sources of tissue
Thirteen tumor specimens were sampled from patients undergoing surgery for endometrial
carcinoma at the University of North Carolina at Chapel Hill. The protocol was reviewed
and exemption granted by the Institutional Review Board at the University of North
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Carolina at Chapel Hill. The international Federation of Gynecology and Obstetrics (FIGO)
stage and histological grade of the tumors are shown in Table 1.
Culture of primary endometrial tumor cells
In brief, the freshly obtained tissues were washed three times in sterile, cold Hank’s
Buffered Salt Solution (HBSS) to remove blood and secretions, and then gently minced by
scissors in M199 medium containing 10% fetal calf serum (FCS) and 0.3 g/l glutamine.
These tumor cells were then incubated for 2–4 h at 37 °C in M199 supplemented with 0.1%
collagenase IA, 100 U/ml penicillin and streptomycin with occasional shaking. After two
centrifugations with PBS wash, the tumor cells were suspended in M199 medium and then
diluted to 1×105 cells/ml. Aliquots (100 μl) of tumor cell suspension were plated into 96
well tissue culture plates resulting in approximately 1×104 cells per well. The cells were
incubated at 37 °C for 24 h in a 5% CO2 incubator, and then were treated with various
concentrations of rapamycin or DMSO. Cell proliferation was assayed by the CellTiter 96
AQ non-Radioactive cell proliferation assay (MTS) from Promega (Madison, WI). After 24,
48 and 72 h, 20 μl of freshly prepared MTS/PMS solution was added to each well, and the
mixture was incubated for 2 h at 37 °C. Optical density was read directly at 490 nm using
ELISA plate reader. All samples were assayed at least in quadruplicate with an appropriate
blank. The tumor inhibition rate (IR %) was calculated for each assay by the formula:
where T=OD 490 of the treated cells and C=OD 490 of the control cells. The tumor was
judged to be sensitive when the IR was ≥50% and insensitive when the IR was <50% at any
of the time points of 24, 48 or 72 h.
Western blotting analysis
Tumor cells at a density of 3×105 cells/well in 6-well plates were cultured for 24 h and then
treated with 20 nM of rapamycin or vehicle (DMSO). Cell lysates were prepared in RIPA
buffer (1% NP-40, 50 mmol/l Tris, 150 mmol/l NaCl). Equal amount proteins were
separated by gel electrophoresis and transferred onto a nitrocellulose membrane. The
membrane was blocked with 5% nonfat milk and then incubated with 1:1000 dilution of
primary antibody overnight at 4 °C. Subsequently, the membrane was washed and incubated
with a secondary peroxidase-conjugated antibody for 1 h after washing. Antibody binding
was detected by using an enhanced chemiluminescence detection system. Western
immunoblotting films were digitized, and band net intensities were quantified suing a
Millipore Digital Bioimaging System (Bedford, MA). After developing, the membrane was
stripped and re-probed using β-actin to confirm equal loading. Western blot films were
digitized, and band net intensities were quantified by a densitometer using the Genegynome
Image System (Sygene, MD). A target protein/β-actin ratio was calculated for each protein.
An endometrial tumor was considered positive for a particular protein if the target protein/β-
actin ratio was ≥0.020.
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Telomere length was assessed by using the TeloTAGGG Telomere Length Assay kit (Roche
Applied Science, Indianapolis, IN), according to the manufacturer’s protocol. DNA was
extracted from the human endometrial cancer tumor specimens using the standard method of
phenol–chloroform. 2 μg of DNA was digested by mixing HinfI (20 U) and RsaI (20 U) and
incubated at 37 °C for 2 h. Resulting DNA fragments were then separated on a 0.8% agarose
gel by electrophoresis in 1× TAE running buffer. Separated DNA was subsequently
transferred to a positively charged nylon membrane and blotted with digoxigenin-labeled
(CCCTAA)3 DNA probe for 3 h at 62 °C. The membrane was exposed to a phosphorimager
screen and detected on the PhosphorImager Storm 860 (Molecular Dynamics, Sunnyvale,
CA) and then on an X-ray film. Median telomere length was calculated using the Image J
freeware (National Institutes of Health, Bethesda, MD).
Real-time PCR for hTERT
Total RNA was isolated using an RNA mini kit, and further DNase treatment was performed
using the RNase-Free DNase Set (QIAGEN, Chatsworth, CA) following the manufacturer’s
instructions. The reverse transcription and PCR reactions were conducted using the TaqMan
Gold one-step PCR kit in the ABI 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA). Reverse transcription was carried out at 48 °C for 30 min. The PCR
condition consisted of a 10 min step at 95 °C and 40 cycles at 95 °C for 15 s and 65 °C for 1
min in a final volume of 30 μl containing 50–100 ng total RNA, 3 μl 10× TaqMan buffer A,
5.5 mM MgCl2, 300 μM dATP, dCTP and dGTP, 600 μM dUTP, 100 nM probe, 200 nM
forward and reverse primer, 15 units RNase inhibitor, 7.5 units MuLV reverse transcriptase
and 1 unit AmpliTaq Gold DNA Polymerase. A housekeeping gene known as acidic
ribosomal phosphoprotein PO (RPLPO) was used as an active and endogenous reference to
correct for differences in the amount of total RNA added to each reaction and to compensate
for different levels of inhibition during reverse transcription of RNA into cDNA during
PCR. Primers and fluorogenic probes for hTERT and RPLPO have been described
previously [13]. The standard curve for quantification of hTERT was generated by using
serial dilutions of a known amount of hTERT cRNA synthesized by in vitro transcription of
a cloned fragment. The level of the hTERT expression of each sample was calculated as a
ratio that the amount of hTERT transcript was divided by the amount of the endogenous
housekeeping gene RPLPO.
Statistical analysis
Results for experiments were normalized to the mean of the control and analyzed using the
Student’s t-test. Differences were considered significant if the p value was less than 0.05
(p<0.05) with a confidence interval of 95%. STATA software (StataCorp, College Station,
TX) was used to perform the statistical analyses.
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Characterization of the Type I and Type II endometrial cancer tumor explants
Thirteen endometrial cancer explants were harvested at the time of hysterectomy. Nine
samples were type I endometrioid adenocarcinomas and four samples were type II serous or
clear cell adenocarcinomas (Tables 1 and 2). ER, PR, wild-type PTEN and phosphorylated-
Akt status was determined for each sample by Western immunoblotting (Fig. 1). All of the
type I and type II tumors expressed PR (target protein/β-actin ratio range of 0.976–0.081),
and 6/9 of the type I and 3/4 of the type II tumors expressed ER (target protein/β-actin ratio
range of 0.00–0.893). Five of the nine (55%) type I tumors expressed wild-type PTEN while
the other four type I tumors (44%) were PTEN negative (target protein/β-actin ratio range of
0.00–0.728). Of the grade 1 endometrioid lesions, two of the three (67%) were PTEN
negative as compared to 3/6 (50%) of the grade 2 or grade 3 lesions. Two of the four type II
tumors (50%) were PTEN negative. Lastly, 8/9 of the type I tumors (89%) and 4/4 (100%)
of the type II tumors expressed phosphorylated-Akt (target protein/β-actin ratio range of
0.00–0.794).
Anti-proliferative effect of rapamycin
We examined the effect of rapamycin in the type I and type II endometrial cancer tumor
explants at 24, 48 and 72 h (Table 1). The IC50 at 48 h is reported in Table 1. Of these
tumors, 9/13 responded to rapamycin, with a median IC50 of 11.4 nM (range 0.01–50 nM).
For the type I tumors, 7/9 (78%) responded to rapamycin (median IC50 of 12.5 nM), and for
the type II tumors, 2/4 (50%) responded to treatment (median IC50 of 7.5 nM). Sensitivity to
rapamycin was independent of PTEN and phosphorylated-Akt status. Rapamycin inhibited
cell growth in 5/7 of the PTEN positive (71%) and 4/6 of the PTEN negative (67%)
endometrial cancers. Only one endometrial tumor was phosphorylated-Akt negative, and
this tumor did not respond to rapamycin. Of the phosphorylated-Akt positive tumors, 9/12
(75%) had a response to treatment with rapamycin.
Effect of rapamycin on the mTOR pathway
To investigate the mechanisms underlying the anti-proliferative effect of rapamycin, we
characterized the effect of this combination treatment on relevant cell signaling targets.
Previous studies suggest that p70S6K is a downstream target of the mTOR pathway [14].
p70S6K kinase directly phosphorylates the 40S ribosomal protein S6, which results in
enhanced synthesis of proteins that contain a polypyrimidine tract in the 5′-untranslated
region [14]. Therefore, we studied the effect of rapamycin on the phosphorylation of the S6
ribosomal protein among the type I and type II endometrial cancer tumor explants. After 24,
48 and 72 h of treatment, rapamycin dramatically decreased the phosphorylation of S6 in all
the endometrial cancer tumor explants by 3.4–13.2 fold (p=0.0001) (Fig. 2A). Little effect
was seen on the expression of total-S6.
mTOR kinase regulates protein synthesis by phosphorylating the translation repressor 4E-
BP-1 on multiple serine/threonine sites [15]. The phosphorylation status of 4E-BP-1
regulates binding to eukaryotic initiation factor 4E (eIF4E). Hyperphosphorylation of 4E-
BP-1 disrupts its binding to eIF4E, activating cap-dependent protein synthesis [16]. After
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24, 48 and 72 h of treatment, rapamycin decreased phosphorylation of 4E-BP-1 (Fig. 2B) in
11/13 of the endometrial cancer tumor explants by 2.8–6.6 fold (p=0.0012). Rapamycin had
little effect on the expression of total-4E-BP-1. Thus, these results suggest that rapamycin’s
effect on either phosphorylated-S6 or phosphorylated- 4E-BP-1 did not correlate with
response to treatment.
Effect of rapamycin on telomere length and hTERT mRNA expression
The hTERT gene encodes the catalytic subunit of telomerase. hTERT expression is the rate-
limiting determinant of the enzymatic activity of human telomerase and is thought to be a
sensitive marker of telomerase function. Real-time RT-PCR was used to quantify hTERT
mRNA expression in the endometrial cancer tumor explant. Treatment with rapamycin (20
nM) decreased hTERT mRNA expression in all of the type I and type II endometrial cancer
tumor explants (Fig. 3). Among these tumors, hTERT mRNA expression was decreased by a
mean of 27% (p=0.0001) (Fig. 3).
Telomere length in the endometrial cancer tumor explants was compared by terminal
restriction fragment southern blot analysis (Fig. 4). The mean telomere length was 7.2 kb for
the type I tumors (range 4.9–10.5 kb) and 8.5 kb for the type II tumors (range 3.8–11.2 kb).
In addition, the mean telomere length was 7.5 for the rapamycin sensitive tumors (3.8–10.8
kb) and 7.8 kb for the rapamycin resistant tumors (4.9–11.2 kb). Thus, the effect of
rapamycin on hTERT mRNA expression or baseline tumor telomere length did not predict
responsiveness to rapamycin in these samples.
Discussion
We have demonstrated activity of rapamycin in both type I and type II endometrial cancer
tumor explants (Tables 1 and 2). Rapamycin universally decreased phosphorylation of S6
and reduced hTERT mRNA expression in all of these tumors, but only inhibited cell
proliferation in 69% of the tumors examined. We found no correlation between PTEN status
or phosphorylated Akt status and response to treatment with rapamycin. Similarly, effects of
rapamycin on phosphorylated S6, phosphorylated 4E-BP-1, hTERT mRNA expression or
baseline telomere length were not predictive of sensitivity to rapamycin. To our knowledge,
this is the first study to evaluate rapamycin in type I and II endometrial cancer tissue
explants and assess potential biomarkers of response for this disease.
Hyperactivation of the PI3K/Akt/mTOR pathway is a feature of many types of cancer,
including endometrial cancer. This can occur by a variety of mechanisms, including PTEN
inactivation which has been found in up to 83% of type I endometrial cancers and 55% of
precancerous lesions [8,17]. Alterations in PTEN occur most frequently by mutations that
lead to loss of function. PTEN and PI3K act as opposing forces to regulate Akt
phosphorylation. PI3K mutations have also been documented in approximately 36% of type
I endometrial cancers and commonly occur in tumors that have PTEN mutations [18]. Loss
of PTEN function in PTEN-null cancer cells has been proposed as an indicator of sensitivity
to rapamycin and its analogues [19–23]. In contrast, others, including our previous work in
endometrial, ovarian and cervical cancer cell lines, have found that loss of PTEN function
was insufficient to predict response to mTOR inhibitors both in vitro and in vivo [12,24–26].
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This present study further supports the lack of correlation between PTEN loss and response
to rapamycin. Among the endometrial cancer tumors examined, a similar percentage of
PTEN positive (71%) and PTEN negative (67%) tumors were sensitive to the growth
inhibitory effects of rapamycin.
The basal level of phosphorylated Akt in cancer cells has also been implicated as another
potential biomarker of responsiveness to mTOR inhibitors, such as rapamycin [23,27].
However, we did not find this to be true among the type I and II endometrial cancer tumor
explants that were evaluated. The vast majority (92%) of the endometrial cancer tumors
expressed basal levels of phosphorylated Akt. Of the endometrial tumors that did not
respond to rapamycin, 2/4 were strongly positive (target/β-actin ratio of 0.460 and 0.794),
1/4 was weakly positive (target/β-actin ratio of 0.077) and 1/4 was negative for
phosphorylated-Akt. It could be argued that a change in phosphorylation after treatment with
rapamycin may be a better predictor of response to therapy. However, in a recent study that
examined the rapamycin analogue, everolimus, Akt phosphorylation induced by everolimus
did not correlate with sensitivity to this treatment in a large panel of different cancer cell
lines [27].
Cell cycle progression necessitates a steady increase in the rate of protein synthesis,
resulting in the coordinated activation of cyclins, cyclin-dependent kinases (CDK) and CDK
inhibitors. Rapamycin is known to block cell cycle progression through G1 by inhibition of
two crucial downstream targets, S6 and 4E-BP-1, which are both mediators of protein
translation. In the search for biomarkers to predict sensitivity to mTOR inhibitors,
phosphorylated S6 and 4E-BP-1 have also been investigated with controversial results.
Rapamycin and its analogues have been shown to inhibit S6 phosphorylation in tumors, skin
and peripheral blood lymphocytes in animal models, and this effect was correlated with the
anti-tumor benefit of rapamycin in these models [28,29]. In addition, it has been proposed
that inhibition of S6 kinase activity in peripheral blood lymphocytes may serve as a
surrogate biomarker for planning optimal dosing regimens of mTOR inhibitors, and this is
being explored in recent clinical trials of the rapamycin analogues, everolimus and
temsirolimus (CCI-779) [29,30]. Inhibition of phosphorylation of 4E-BP-1 by temsirolimus
has also been correlated with the degree of tumor growth inhibition in prostate, glioma and
ovarian carcinoma xenograft animal models [31]. We found that rapamycin decreased
phosphorylation of S6 in all of the endometrial cancer tumor explants examined and
decreased phosphorylation of 4E-BP-1 in most of these tumors (85% or 11/13 tumors).
These results are most consistent with what has been shown in studies of breast, prostate and
multiple myeloma cells, where S6 and 4E-BP-1 phosphorylation was inhibited in both
rapamycin-sensitive and rapamycin-resistant cancer cell lines [20,22,23]. Thus, inhibition of
phosphorylation of S6 and 4E-BP-1 may indicate that adequate target inhibition has been
achieved, but may not serve as useful biomarkers of sensitivity to mTOR inhibitor therapy.
These findings suggest that additional pathways other than the mTOR pathway may
modulate cellular proliferation or alternatively, that S6 and 4E-BP-1 may not be the only
critical downstream effectors of mTOR signaling. In further support of this hypothesis, in a
phase I trial of everolimus in 55 patients with advanced solid tumors, treatment resulted in
almost complete inhibition of phosphorylation of S6 and 4E-BP-1 in tumor and skin samples
but this did not predict sensitivity to therapy [30,32].
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Telomeres are structures that cap the ends of chromosomes. As cells get older, telomeres
progressively shorten and ultimately reach a crisis point that leads an older potentially
defective cell towards cell death. Telomerase is an enzyme that adds DNA sequence repeats
(TTAGGG) to the 3′ end of the DNA telomere region, thereby preventing the shortening of
the caps at the ends of chromosomes. In most normal somatic cell types, telomerase activity
is usually undetectable; however, the endometrium is a unique exception [33]. Telomerase
activity rises and falls throughout the menstrual cycle, with high levels found during the
proliferative phase and low levels during the secretory phase. It is hypothesized that these
fluctuations in telomerase activity may be linked to the ability of the normal endometrium to
repeatedly proliferate from the onset of menarche to menopause. Activation of telomerase
enables cells to divide indefinitely and has been implicated as a key element in cellular
immortality and oncogenesis for many cancers [33], including endometrial cancers [34,35].
Expression of telomerase has been documented in over 90% of endometrial cancers [34,35].
Telomerase is comprised of an RNA template (hTR) and the catalytic protein hTERT which
has reverse transcriptase activity. hTERT is considered to be the rate-limiting factor in the
formation of functional telomerase.
Based on our previous work, the mTOR signaling pathway may also play a role in the
regulation of telomerase activity. We have previously shown that rapamycin potently
suppressed telomerase activity by decreasing hTERT mRNA levels in endometrial, ovarian
and cervical cancer cell lines [12,24]. Although controversial, it has been suggested that
hTERT transcription is cell cycle dependent and that non-cycling cells do not express
hTERT [36,37]. Thus, one could argue that the effect of rapamycin on decreasing hTERT
expression may occur simply as an indirect consequence of cell cycle arrest rather than a
direct effect on hTERT transcription. However, we found that rapamycin globally decreased
hTERT expression in gynecologic cancer cell lines, even in cell lines that were resistant to
rapamycin’s anti-proliferative effects and failed to undergo G1 arrest [24]. This is further
supported by our findings in the type I and II endometrial cancer tissue explants. Rapamycin
decreased hTERT expression in all of these tumors, independent of the responsiveness of
these tumors to rapamycin’s growth inhibitory effects. Thus, rapamycin may regulate
hTERT mRNA expression through an alternative pathway downstream from mTOR that is
distinct from its ability to induce cell cycle arrest.
Telomere length has also been implicated as a prognostic indicator in a number of solid
tumors, including breast, colon, lung, prostate and hepatocellular carcinomas [38]. In
general, alterations in telomere length are associated with worse clinical outcomes, but the
type of alteration, i.e. short versus long telomeres, appears to be dependent on the tumor
type [38]. Given the potential relationship between mTOR signaling and telomerase activity,
we measured telomere length to see if this would correspond to response to treatment.
Although effects on hTERT expression failed to predict sensitivity to rapamycin among the
endometrial cancer tissue explants, our hope was that differences in telomere length may be
more helpful. However, the mean telomere length was the same between rapamycin
sensitive and resistant tumors; and thus, was not a biomarker of response to this drug.
Biomarkers to predict sensitivity to mTOR inhibitors have remained elusive both in pre-
clinical studies and in clinical trials for endometrial cancer as well as other tumor types. As
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demonstrated in our work, PTEN and phosphorylated Akt status failed to predict sensitivity
to treatment with rapamycin among type I and type II endometrial cancer tumor explants. A
number of other potential biomarkers were explored, including phosphorylated S6,
phosphorylated 4E-BP-1, hTERT and telomere length, but none were found to be effective
in discriminating which tumors would best respond to the anti-proliferative effects of
rapamycin treatment. Our numbers are small, and this limitation could have impacted the
emergence of one of these factors as a legitimate biomarker. However, these findings are
consistent with those from recent clinical trials of mTOR inhibitors in endometrial cancer.
Three mTOR inhibitors have been or are currently being investigated in women with
endometrial cancer: temsirolimus (CCI-779, Wyeth), everolimus (RAD001, Novartis) and
ridaforolimus (formerly deforolimus, AP23573, Merck). According to the results from the
completed phase II trials to date, mTOR inhibitors do exhibit activity in women with
advanced or recurrent endometrial cancer [7], with response rates of 26–28%. Based on the
biologic correlates derived from some of these trials, response to mTOR inhibitors has not
correlated with PTEN status or Akt and mTOR expression patterns [7]. Although loss of
PTEN is more commonly associated with type I tumors, there is no indication that mTOR
inhibitors are not equally efficacious in type II tumors and other molecular characteristics
may ultimately be the more critical factor in predicting sensitivity or alternatively, resistance
to treatment. It is possible that alternative approaches such as microarray gene expression
profiling may lead to identification of biomarkers predicting sensitivity to mTOR inhibition.
Thus, the search continues for meaningful biomarkers or combinations of biomarkers to help
identify endometrial cancer patients who are most likely to benefit from mTOR inhibitor
therapy, and this should continue to be a priority goal in subsequent clinical trials and
translational studies.
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Expression of the progesterone receptor (PR), estrogen receptor (ER), PTEN,
phosphorylated-AKT (P-Akt) and β-actin in 13 human endometrial cancer tumor explants by
Western blotting.
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Rapamycin inhibited phosphorylation of S6 in all of the human endometrial cancer tumor
explants as determined by Western blotting [A]. In addition, rapamycin decreased
phosphorylation of 4E-BP-1 in most of these tumor explants (77% or 10/13) [B]. Primary
tumor cells were cultured for 24 h and then treated with 20 nM rapamycin (Ra) or control
(C) for 24, 48 or 72 h. Little effect was seen on total S6 or total 4E-BP-1. This is a
representative Western blot of 4 of the 13 endometrial cancer tumor explants examined.
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Rapamycin inhibits hTERT mRNA expression in human endometrial cancer tumor explants.
Primary tumor cells were cultured for 48 h and then treated with 20 nM rapamycin or
control for 48 h. hTERT mRNA levels were determined by real-time RT-PCR.
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Comparison of telomere length in human endometrial cancer tumor explants by terminal
restriction fragment Southern blot analysis. Telomere length did not predict responsiveness
to rapamycin among these samples.
Bae-Jump et al. Page 16











































Bae-Jump et al. Page 17
Table 1
Characterization of endometrial cancer explants treated with rapamycin.





1 endometrioid 2 IB a + −
2 endometrioid 3 IB 50 − +
3 serous 3 IA 0.01 − +
4 endometrioid 3 IB 1 + +
5 endometrioid 3 IB 10 + +
6 clear 3 IB a + +
7 endometrioid 1 IB 1 + +
8 serous 3 IB a − +
9 endometrioid 3 IB a − +
10 clear 3 IVB 15 + +
11 endometrioid 1 IB 0.01 − +
12 endometrioid 2 IA 25 + +
13 endometrioid 1 IA 0.5 − +
a
Did not respond to treatment with rapamycin.
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Table 2
Rapamycin in type I and type II endometrial cancers.
Type Type I (n = 9) Type II (n = 4)
Mean IC50 12.5 nM (7/9) samples
responded
7.5 nM (2/4 samples
responded)
ER status 6/9 positive 3/4 positive
PR status 9/9 positive 4/4 positive
Wildtype-PTEN status 5/9 positive 2/4 positive













Mean telomere length 7.2 kb 8.5 kb
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